1 The EIC Accelerator Project

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support innovative start-ups and small and medium-sized enterprises (SMEs) with high-risk, high-potential projects that aim to develop groundbreaking technologies or services. This initiative aligns with the EU's strategic goal of fostering innovation and competitiveness within the European economy, particularly in the DeepTech sector.

Funding Structure

The EIC Accelerator offers a unique blend of funding options to support the growth and scalability of innovative ventures. The funding is divided into two primary components: grants and equity.

Purpose and Impact

The EIC Accelerator is pivotal in the European DeepTech and startup ecosystem, as it not only provides financial resources but also strategic guidance and mentorship. It aims to bridge the funding gap that many innovative companies face, especially in the early stages when traditional investors may be hesitant to commit. By facilitating access to both public and private funding, the EIC Accelerator plays a crucial role in helping companies validate their technology and business models, thereby increasing their attractiveness to private investors.

Case Study: BIOSIMULYTICS LIMITED

Company Overview: BIOSIMULYTICS LIMITED, based in Ireland, is a prime example of a recipient of the EIC Accelerator funding. The company focuses on advancing biopharmaceutical development through innovative simulation technologies.

Project Overview: The EIC Accelerator project titled "BioSim M2M: Molecules to Medicine" is aimed at revolutionizing the drug development process. The project seeks to create a comprehensive platform for simulating biological processes at the molecular level, thereby accelerating the journey of potential therapeutics from the lab to clinical application.

Technology Background

The technology underpinning the BioSim M2M project is rooted in advanced computational modeling and simulation techniques. Traditional drug development processes are often lengthy, expensive, and fraught with uncertainty. By employing sophisticated algorithms and data analytics, BIOSIMULYTICS aims to streamline the discovery and optimization of drug candidates.

Key Features of the Technology:

Conclusion

The EIC Accelerator program serves as a vital catalyst for innovative companies like BIOSIMULYTICS LIMITED, providing both essential funding and strategic support to scale their operations. The BioSim M2M project exemplifies how cutting-edge technology can transform the drug development landscape, ultimately paving the way for more efficient and effective medical treatments. Through initiatives like the EIC Accelerator, the European Union is fostering a robust ecosystem of innovation that promises to enhance competitiveness and drive economic growth across the continent.

2 The Funding Rounds

BIOSIMULYTICS LIMITED: Financing and Funding Activity Since EIC Accelerator Award

Overview

BIOSIMULYTICS LIMITED, an Irish spin-out from University College Dublin (UCD), specializes in AI-driven software for pharmaceutical R&D. The company was among four Irish firms to secure funding approvals under the European Innovation Council (EIC) Accelerator Programme, following the March 22, 2023 cut-off.

---

Financing Raised and Funding Rounds

Pre-EIC Accelerator Funding:

• Seed Round: In September 2021, Biosimulytics raised €595,000 in seed capital. This round included investments from angel investors and Enterprise Ireland.
• Earlier Support: The company won UCD’s VentureLaunch accelerator (€32,000 cash prize) in November 2019 and received initial support as a university spinout starting January 2019.

EIC Accelerator Funding (Post-March 2023):

Grant & Equity: Following its successful application to the EIC Accelerator (cut-off March 22, 2023), Biosimulytics secured approval for up to €2.5 million in grant funding combined with an equity investment ranging from €0.5 million to €15 million through a blended finance offer. Public reports indicate that this round was formally announced on June 20–21, 2023.

Other Grants:

Additional grants include a reported award of approximately $215k from EIT Digital Accelerator and about $1.5k from EIT Health as of January 2022; however these are smaller compared to the major rounds above.

---

Timing and Amounts of Major Rounds

Date	Round Type	Amount Raised	Investors/Source
Jan/Nov '19	Spinout/Competition	Undisclosed/€32k	UCD/NovaUCD
Sep '21	Seed	€595k	Angel investors, Enterprise Ireland
Jan '22	Grant	~$215k / ~$1.5k	EIT Digital/EIT Health
Jun '23	Grant & Equity	Up to €2.5m grant + equity up to €15m	European Innovation Council

<em class="publication">The full details of equity investment drawn down by Biosimulytics under the EIC scheme have not been publicly specified; approvals cover these ranges but actual drawdown may vary.

---

Investor Information

Notable investors across different rounds: - Enterprise Ireland: Participated actively since at least seed stage.

• European Innovation Council (EIC): Lead financier via its blended grant/equity mechanism.
• Angel Investors: Participated during seed round.
• EIT Digital/EIT Health: Provided smaller innovation grants or awards.

Biosimulytics also benefited significantly from institutional support as a High Potential Start-Up client within Enterprise Ireland’s broader commercialization programs.

---

Company Valuations

No public disclosures specify post-money valuations for any funding rounds regarding Biosimulytics Limited as of May 2025. While total reported raised capital is approximately $740K according to some sources—excluding undrawn or pending elements of larger grants/equity—there is no formal valuation data released by either the company or major databases at this time. Given their recent significant EU-level backing and plans toward Series A after industrial validation (anticipated within two years post-seed), valuations are likely evolving but undisclosed.

---

Exit Events: IPOs, Buyouts or Acquisitions

No exit events—including IPOs, buyouts or acquisitions—have been reported for BIOSIMULYTICS LIMITED up until May 2025 based on all available sources reviewed here.

---

Summary Table: Major Publicly Reported Fundings Since Founding

| Year | Event/Funding Round | Approximate Amount | |----------|-------------------------------|---------------------| | Nov ’19 / Jan ’19 Spin-out/UCD Prize €32K+ | | Sep ’21 Seed €595K | | Jan ’22 EIT Digital/EIT Health ~$216K total | | Jun ’23 EIC Accel.: Grant+Equity up to ~€17.5M allowed |

*VentureLaunch win date; spinout date per public records.

Sources

• Biosimulytics Secures European Innovation Council Accelerator Programme Funding
• NovaUCD's BioSimulytics raises €595,000 of seed capital
• BioSimulytics Secures €595k in Seed Funding
• BioSimulytics Stock Price, Funding & Financial Data – CB Insights
• €18m funding win for four Enterprise Ireland client companies...
• Four Irish start-ups win funding at Horizon Europe's...

All information above pertains specifically to BIOSIMULYTICS LIMITED with no unrelated results included.

3 The Press Releases

Biosimulytics: Post-EIC Accelerator Funding Developments Biosimulytics, an Irish AI-driven pharma software company and University College Dublin (UCD) spin-out, secured EIC Accelerator funding in June 2023 following its March 2023 proposal submission. The funding includes up to €2.5 million in grants and equity investments ranging from €0.5 million to €15 million, aimed at scaling its drug development platform.

Technology Advancements
The company’s core innovation is a quantum physics-based AI/ML platform that accelerates drug discovery by predicting molecular behavior, reducing risks in transitioning from molecules to medicine (M2M). Their proprietary technology focuses on crystal structure prediction (CSP) and structure-based drug design (SBDD), critical for optimizing drug stability and efficacy.

Strategic Partnerships
In a pivotal move, Biosimulytics entered an exclusive HPC cloud partnership with CGG, a global HPC leader. This collaboration provides a customized high-performance computing environment that accelerates molecular simulations five times faster than previous solutions, enabling rapid scalability for pharmaceutical clients.

Commercial Traction & Recognition
By late 2022, Biosimulytics secured its first purchase order from a U.S. biotech firm for cancer drug development assistance. In 2024, the company was named a finalist for the EIT Innovation Team Award—Europe’s top deep-tech honor—for its multidisciplinary approach integrating AI and quantum physics.

---

Sources

• EIC Accelerator winners March 2023
• Biosimulytics Secures EIC Accelerator Funding
• HPC Cloud Partnership with CGG
• EIT Awards Finalist Announcement
• CGG Case Study on Biosimulytics.pdf)

4 The Technology Advancements

BioSimulytics Limited: Current Capabilities and Recent Advancements

BioSimulytics Limited, an Irish company founded in 2019 as a spin-out from the University College Dublin (UCD) School of Chemical and Bioprocess Engineering, specializes in AI-enhanced molecular modeling. The company combines artificial intelligence, quantum physics, computational chemistry, and high-performance computing to improve drug development processes.

Current Capabilities

BioSimulytics focuses on predicting the crystal structures of drug molecules and their binding poses in protein-ligand complexes, crucial for structure-based drug design (SBDD) and computer-aided drug design (CADD). Their technology aims to reduce the time and cost associated with bringing new drugs to market by providing accurate simulations of molecular behaviors.

Advancements Since EIC Accelerator Funding

Following the receipt of EIC Accelerator funding in March 2023, BioSimulytics has made significant advancements. The company has secured funding to scale its innovative platform, which integrates AI, quantum physics, and high-performance computing to optimize drug development processes. This funding will be instrumental in expanding their team, enhancing their product roadmap, and increasing their customer base.

Technology Improvements and Market Demonstration

BioSimulytics entered an exclusive HPC cloud partnership with CGG, enabling them to scale their technology and provide pharmaceutical companies with powerful predictive simulations. This partnership allows BioSimulytics to run applications at least five times faster than before, enhancing their return on investment and business expansion capabilities. While specific details on new features or demonstrations with customers since March 2023 are not available, the partnership with CGG is a significant step in deploying their technology effectively in the market.

Patents, Scientific Studies, and Clinical Trials

There is no published information on new patents filed or scientific studies initiated specifically since the EIC funding. However, BioSimulytics continues to leverage its foundational breakthroughs in quantum physics and AI to enhance drug development processes.

Sources

• BioSimulytics
• Biosimulytics Limited
• NovaUCD's BioSimulytics becomes 2024 EIT Awards finalist
• Biosimulytics in HPC cloud partnership with CGG to progress market adoption of its AI drug development tech
• NovaUCD's BioSimulytics raises €595,000 of seed capital
• €18m funding win for four Enterprise Ireland client companies in Horizon Europe EIC Accelerator
• Biosimulytics Enters Exclusive HPC Cloud Partnership with CGG to Accelerate Market Adoption of its AI Drug Development Technology
• Biosimulytics Secures European Innovation Council Accelerator Programme Funding

5 The Partnerships and Customers

BIOSIMULYTICS LIMITED: Partnerships and Advancements

BIOSIMULYTICS LIMITED, an Irish company based at NovaUCD in Dublin, has been making significant strides in the pharmaceutical technology sector since receiving the EIC Accelerator funding in 2023. The company specializes in AI-powered software solutions for drug development, leveraging technologies like artificial intelligence, quantum physics, and high-performance computing (HPCassistant

BIOSIMULYTICS LIMITED: Partnerships and Advancements

BIOSIMULYTICS LIMITED, an Irish company based at NovaUCD in Dublin, has been making significant strides in the pharmaceutical technology sector since receiving the EIC Accelerator funding in 2023. The company specializes in AI-powered software solutions for drug development, leveraging technologies like artificial intelligence, quantum physics, and high-performance computing (HPC).

Partnerships

One of the key partnerships for BIOSIMULYTICS LIMITED is with CGG, a global technology and HPC leader. CGG has been selected as the exclusive HPC cloud partner for BIOSIMULYTICS LIMITED, providing customized HPC, AI, and cloud solutions. This partnership significantly enhances BIOSIMULYTICS LIMITED's ability to scale its pharmatech platform, enabling pharmaceutical companies to develop new drug molecules more efficiently. The use of CGG's solutions allows BIOSIMULYTICS LIMITED to run applications at least five times faster than its previous cloud setup, thereby improving its return on investment and expanding its business reach.

Customers

While specific customer names are not detailed in the available information, BIOSIMULYTICS LIMITED works with leading pharmaceutical companies worldwide. Its platform is designed to provide these companies with predictive simulation capabilities that enhance the speed, cost-effectiveness, and success rate of drug development.

New Relationships and Partnerships

As part of its recent advancements, BIOSIMULYTICS LIMITED has secured significant funding from the EIC Accelerator program, which is part of the Horizon Europe initiative. This funding supports the company's ambition to scale its unique pharmatech platform globally, addressing bottlenecks in the drug development process.

Nature and Purpose of New Relationships

The new relationships, such as the partnership with CGG and the support from the EIC Accelerator, are aimed at enhancing BIOSIMULYTICS LIMITED's technological capabilities and market reach. These collaborations enable the company to accelerate its product roadmap and become more investor-ready, positioning itself as a key player in the rapidly expanding AI-powered drug development market.

Market Positioning

BIOSIMULYTICS LIMITED's partnerships and funding will position it as a leader in providing AI-driven solutions for pharmaceutical R&D. By leveraging cutting-edge technologies, the company aims to reduce the time and cost associated with drug development, making it a vital partner for pharmaceutical companies seeking to advance their pipelines efficiently.

Technology Advancements and Scaling

The partnerships and funding received by BIOSIMULYTICS LIMITED are crucial for advancing its technological capabilities. The company's software combines AI, machine learning, computational chemistry, quantum physics, and high-performance computing to predict the crystal structures of molecules accurately. This approach not only speeds up the development process but also increases its success rate, helping to avoid costly mistakes in drug development.

Sources

• CGG Awarded Exclusive Contract To Provide HPC Cloud Solutions To Biosimulytics For AI-Powered Drug Development
• Newsroom - Viridien
• €18m funding win for four Enterprise Ireland client companies in Horizon Europe EIC Accelerator
• BioSim M2M: Molecules to Medicine - CORDIS
• BioSimulytics Secures €595k in Seed Funding
• NovaUCD's BioSimulytics raises €595,000 of seed capital

6 The Hiring and Company Growth

BioSimulytics Team Growth and Hiring Strategy BioSimulytics, an AI-driven molecular modeling company spun out of University College Dublin (UCD), has demonstrated steady growth since its 2019 founding. While the exact current headcount remains undisclosed, the team structure includes CEO Peter Doyle, CTO Niall English, Head of R&D Christian Burnham, computational scientist Mozhdeh Shiranirad, and business development lead Paul Kilroy-Glynn.

The company actively promotes team expansion, listing open roles for scientists and innovators on its website under "Join our growing team," though specific positions or hiring numbers are not detailed. Its growth trajectory includes raising €595,000 in a 2021 seed round to expand its technical team and client base in EU/US markets, followed by plans for a Series A round within two years post-seed funding.

Key Developments Post-2023 EIC Accelerator Submission
While direct hiring data post-March 2023 is unavailable from public sources:

• Core leadership remained stable, with no management changes reported since its founding.
• Recent hires likely focus on computational scientists and AI specialists to scale its drug-discovery platform, which combines neural networks and high-performance computing for polymorph prediction.
• Growth aligns with market trends favoring cloud-based biosimulation tools (projected 16.7% CAGR through 2029), positioning BioSimulytics to capitalize on pharma’s shift toward digital R&D strategies.

---

Sources

• BioSimulytics - AI-enhanced molecular modelling
• NovaUCD's BioSimulytics raises €595,000 of seed capital
• UCD Start-up of the Year BioSimulytics awarded €32,000 prize
• Next-generation digital platform for faster drug development (PDF)

7 The Media Features and Publications

BioSimulytics Limited: Recent Developments and Media Features

BioSimulytics Limited, an Irish company specializing in AI-enhanced molecular modeling, has gained significant recognition in the pharmaceutical industry. Since receiving funding, the company has been involved in various media features, publications, and events.

Media Features

BioSimulytics was named a finalist for the 2024 EIT Awards, specifically for the EIT Innovation Team Award, due to its innovative AI-based software designed to enhance drug development speed and success. The company's technology combines quantum physics, computational chemistry, machine learning, and high-performance computing to predict drug compound properties and improve drug design processes.

Publications

The company has been featured in publications such as Silicon Republic and Science Business, highlighting its breakthrough technology in molecular modeling and its potential to accelerate drug development. A core publication discussing the underlying principles of BioSimulytics' method was featured in the Journal of Chemical Theory & Computation, focusing on its application to water-ice molecules.

Podcasts and Interviews

Peter Doyle, CEO of BioSimulytics, has been involved in pitching the company at events like Enterprise Ireland's Big Ideas, where he discussed the company's vision and technology.

Conference and Fair Visits

BioSimulytics has participated in significant partnerships, including an exclusive HPC cloud partnership with CGG, which supports the company's technology deployment across the global pharmaceutical industry. This partnership enhances the company's ability to serve clients with secure and legally protected cloud services.

Event Involvement

The company was a winner of the UCD VentureLaunch Accelerator Programme in 2019, receiving a €32,000 prize and recognition for its innovative approach to drug development. BioSimulytics continues to engage with leading pharmaceutical companies and research institutions, leveraging its technology to drive advancements in drug research and development.

Sources

• BioSimulytics
• NovaUCD's BioSimulytics becomes 2024 EIT Awards finalist
• BioSimulytics wins University College Dublin's 2019 start-up of the year award
• Enterprise Ireland Big Ideas 2020 - Peter Doyle BioSimulytics Limited
• BioSimulytics Enters Exclusive HPC Cloud Partnership with CGG to Accelerate AI Technology Adoption